Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2025 | $92.00 → $107.00 | Neutral → Buy | Citigroup |
| 10/10/2024 | $98.00 → $105.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 8/21/2024 | $92.00 → $94.00 | Perform | Oppenheimer |
| 8/15/2024 | $76.00 → $90.00 | Sell → Neutral | UBS |
| 8/14/2024 | $100.00 → $85.00 | Buy → Hold | Stifel |
| 5/30/2024 | $83.00 | Sell | Goldman |
| 7/19/2023 | $90.00 | Neutral | Robert W. Baird |
| 6/30/2023 | $106.00 | Buy | CL King |
One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal AfibDual-energy (RF/PF), focal Sphere-9™ catheter demonstrates efficacy for linear ablation in persistent AFibMedtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meetingGALWAY, Ireland and SAN DIEGO, April 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family of techno
Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as a late-breaker at the American Urologic Association annual meeting Company confirms Hugo RAS system submission to the U.S. Food and Drug Administration GALWAY, Ireland and LAS VEGAS, April 26, 2025 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption (IDE) clinical study, the largest such study for robotic-assisted urologic surgery ever conducted, met both primary safety and effectiveness endpoints. The prospective, multi-center, single-arm IDE stu
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: Late-breaking clinical study results evaluating the OmniaSecure lead for investigational use in the LBBAP location show high defibrillation success GALWAY, Ireland and SAN DIEGO, April 25, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure™ defibrillation lead for placement within the right ventricle. The lead, built on the highly reliable SelectSecure™ Model 3830 pacing lead and delive
Citigroup upgraded Medtronic from Neutral to Buy and set a new price target of $107.00 from $92.00 previously
RBC Capital Mkts upgraded Medtronic from Sector Perform to Outperform and set a new price target of $105.00 from $98.00 previously
Oppenheimer reiterated coverage of Medtronic with a rating of Perform and set a new price target of $94.00 from $92.00 previously
3 - Medtronic plc (0001613103) (Issuer)
4/A - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
8-K - Medtronic plc (0001613103) (Filer)
10-Q - Medtronic plc (0001613103) (Filer)
8-K - Medtronic plc (0001613103) (Filer)
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for
Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a
GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquart
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported and 4.1% organicGAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7%Company reiterates full year revenue and EPS guidanceCardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) productsU.S. Centers for Medicare and Medic
GALWAY, Ireland, Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025, to shareholders of record at the close of business on December 27, 2024. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)